Immatics N.V. (IMTX)
Nasdaq · Healthcare · Biotechnology
$7.73+1.84%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $1.2B
- 52-week range
- $7.40 – $12.41
- 52-week change
- −19.34%
- EPS (trailing)
- −$1.87
- Next earnings
- Nov 17, 2026
About Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial.
Headquarters: Tübingen, Germany · 704 employees · immatics.com